All In Biotech

NDA 022301 · Salix

Apriso

Mesalamine · Oral · Aminosalicylate

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Oct 31, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

188

77 Phase 3, 14 recruiting

FAERS reports

30,554

25,825 serious, 2,014 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 22, 2026.

APRISO ® is indicated for the maintenance of remission of ulcerative colitis in adults. APRISO is an aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults. ( 1 )

Mechanism: The mechanism of action of mesalamine (5-ASA) is not fully understood, but appears to be a local anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with ulcerative colitis, and it is possible that 5-ASA diminishes inflammation by blocking production of arachidonic acid metabolites.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • APRISO · MESALAMINE 375MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mesalamine" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6,630
  • colitis ulcerative4,783
  • drug ineffective4,670
  • condition aggravated3,464
  • diarrhoea2,886
  • haematochezia2,547
  • fatigue2,406
  • abdominal pain2,291
  • headache2,031
  • weight decreased2,024
  • nausea2,010
  • pyrexia1,905

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004106
2005149
2006106
2007150
2008570
2009123
2010273
2011756
2012701
2013320
2014454
2015667
2016694
2017692
2018853
2019976
20201,339
20212,521
20224,243
20234,356
20244,073
20254,029
20262,402

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Apriso (Mesalamine)

2024 spending

$5.2M

Beneficiaries

1,465

6,392 claims

Per beneficiary

$3,579

$4.08 per unit

View as table
YearSpending
2020$28,089,239
2021$13,566,619
2022$8,495,149
2023$6,835,481
2024$5,242,803

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 263 on PubMed

Sponsor: Salix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.